Manuscripts and Publications

2022
Belz DC, Woo H, Putcha N, Paulin LM, Koehler K, Fawzy A, Alexis NE, R Barr G, Comellas AP, Cooper CB et al..  2022.  Ambient ozone effects on respiratory outcomes among smokers modified by neighborhood poverty: An analysis of SPIROMICS AIR. Sci Total Environ. 829:154694.
Weiss JR, Serdenes R, Madtha U, Zhao H, Kim V, Lopez-Pastrana J, Eakin MN, O'Toole J, Cooper CB, Woodruff P et al..  2022.  Association Among Chronic Obstructive Pulmonary Disease Severity, Exacerbation Risk, and Anxiety and Depression Symptoms in the SPIROMICS Cohort.. J Acad Consult Liaison Psychiatry.
Krishnan JK, Ancy KM, Oromendia C, Hoffman KL, Easthausen I, Leidy NK, Han MK, Bowler RP, Christenson SA, Couper DJ et al..  2022.  Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument. Chronic Obstr Pulm Dis. 9(2):195-208.
Iyer AS, Parekh TM, O'Toole J, Bhatt SP, Eakin MN, Krishnan JA, Yohannes AM, Woodruff PG, Cooper CB, Kanner RE et al..  2022.  Clinically Significant and Comorbid Anxiety and Depression Symptoms Predict Severe Respiratory Exacerbations in Smokers: A Post Hoc Analysis of the COPDGene and SPIROMICS Cohorts. Ann Am Thorac Soc. 19(1):143-146.
O'Toole J, Woo H, Putcha N, Cooper CB, Woodruff P, Kanner RE, Paine R, Bowler RP, Comellas A, Hoth KF et al..  2022.  Comparative Impact of Depressive Symptoms and FEV% on Chronic Obstructive Pulmonary Disease.. Ann Am Thorac Soc. 19(2):171-178.
Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG et al..  2022.  Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.. Chronic Obstr Pulm Dis. 9(2):111-121.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.
Godbole S, Labaki WW, Pratte KA, Hill A, Moll M, Hastie AT, Peters SP, Gregory A, Ortega VE, Demeo D et al..  2022.  A Metabolomic Severity Score for Airflow Obstruction and Emphysema.. Metabolites. 12(5)
Wang D, Pan Y, Durumeric OC, Reinhardt JM, Hoffman EA, Schroeder JD, Christensen GE.  2022.  PLOSL: Population learning followed by one shot learning pulmonary image registration using tissue volume preserving and vesselness constraints.. Med Image Anal. 79:102434.
Buhr RG, Barjaktarevic IZ, P Quibrera M, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN et al..  2022.  Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. Am J Respir Crit Care Med. 206(5):554-562.
Baugh A, Buhr RG, Quibrera P, Barjaktarevic I, R Barr G, Bowler R, Han MKing, Kaufman JD, Koch AL, Krishnan J et al..  2022.  Risk of COPD exacerbation is increased by poor sleep quality and modified by social adversity.. Sleep. 45(8)
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
2021
Burkes RM, Couper DJ, Barjaktarevic IZ, Cooper CB, Labaki WW, Han MK, Woodruff PG, Lazarus SC, Parekh TM, Paine R et al..  2021.  Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS.. Chronic Obstr Pulm Dis. 8(2):277-291.
Radicioni G, Ceppe A, Ford AA, Alexis NE, R Barr G, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN et al..  2021.  Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 9(11):1241-1254.
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
Ejike CO, Woo H, Galiatsatos P, Paulin LM, Krishnan JA, Cooper CB, Couper DJ, Kanner RE, Bowler RP, Hoffman EA et al..  2021.  Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.. Am J Respir Crit Care Med. 203(8):987-997.
Oh AL, Mularski RA, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Criner GJ, Han MK, Hansel NN et al..  2021.  Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.. Ann Am Thorac Soc. 18(11):1822-1831.
Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ et al..  2021.  Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.. Genome Med. 13(1):66.
Turnier L, Eakin M, Woo H, Dransfield M, Parekh T, Krishnan JA, Kanner R, Cooper CB, Woodruff PG, Wise R et al..  2021.  The influence of social support on COPD outcomes mediated by depression.. PLoS One. 16(3):e0245478.
Li F, Choi J, Zou C, Newell JD, Comellas AP, Lee CHyun, Ko H, R Barr G, Bleecker ER, Cooper CB et al..  2021.  Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images.. Sci Rep. 11(1):4916.
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
Zusman M, Gassett AJ, Kirwa K, R Barr G, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Rd RPaine et al..  2021.  Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study.. Indoor Air. 31(3):702-716.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.

Pages